Chest
-
OSA & COPD PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: OSAS is an independent risk factor for asthma exacerbations and OSAS symptoms are more common in asthmatic patients than in the general population. This study correlates number of exacerbations with AHI in 24 stable asthmatics with overlap of OSAMETHODS: 24 stable patients' of BA with overlap of OSA diagnosed on PSG, using or not using CPAP, attending outpatient clinic of Metro Centre for Respiratory diseases were retrospectively analysed for number of exacerbations in last one year using SPSS software. ⋯ The following authors have nothing to disclose: Mayuri Johari, Karn Mehra, Deepak TalwarNo Product/Research Disclosure Information.
-
Late Breaking AbstractsSESSION TYPE: Slide PresentationPRESENTED ON: Saturday, March 22, 2014 at 09:00 AM - 10:00 AMPURPOSE: Bevacizumab is an anti-angiogenic agent used in many advanced solid tumours, including non-squamous NSCLC. In contrast to clinical studies, that all patients are fit, we retrospectively try to evaluate safety of Bv in superannuated population ⋯ The following authors have nothing to disclose: Andriani Charpidou, Dimitrios Vassos, Sotirios Tsimpoukis, Panagiotis Demertzis, Ioannis Gkiozos, Kostas SyrigosNo Product/Research Disclosure Information.
-
Critical Care Posters IISESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: To determine the characteristics of patients with community-acquired pneumonia and mild acute respiratory distress syndrome (CAP-mild ARDS) who require ICU admission. ⋯ The following authors have nothing to disclose: Laura Novella, Francisco Sanz, Estrella Fernández-Fabrellas, Ángela Cervera, Maria Luisa Briones, María Carmen Aguar, Ruben Lera, Eusebi Chiner, Javier Berraondo, Susana Herrera, Cristina Miralles, Marí Climent, Dolores Martinez, Lucia Gil, José BlanquerNo Product/Research Disclosure Information.
-
COPD QVA149 PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Patients with severe-to-very severe COPD require intensified therapy to reduce risk of exacerbations. Such patients may benefit from additional bronchodilation. Once-daily QVA149 is a dual bronchodilator consisting of a fixed-dose combination of two long-acting bronchodilators, indacaterol and glycopyrronium. ⋯ Jadwiga Wedzicha: Consultant fee, speaker bureau, advisory committee, etc.: JW has received speaking fee and/or for advisory boards from GlaxoSmithKline, AstraZeneca, Novartis, Bayer, Boehringer Ingelheim, Nycomed. Chiesi and Respifor as well as travel reimbursements from Boehringer Ingelheim. JW has received research grants from GlaxoSmithKline, AstraZeneca, Chiesi and Novartis. Joachim Ficker: Consultant fee, speaker bureau, advisory committee, etc.: Dr. Ficker has received speaker fees from AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Pfizer, Nycomed, Almirall, Berlin-C hemie, Takeda and Novartis, consulting fees from AstraZeneca, Boehringer Ingelheim, and Novartis. Angel FowlerTaylor: Employee: The author is an employee of Novartis Pharmaceuticals Corporation Donald Banerji: Employee: The author is an employee of Novartis Pharmaceuticals Corporation The following authors have nothing to disclose: Dennis Niewohner, Thomas SandströmClinical trial results of QVA149, combination of two approved products indacaterol and glycopyrronium, will be presented, QVA149 is in the late stage phase 3 trials prior to approval.
-
Surgery Case Report Posters IISESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: Chest wall tumors are rarely seen in the manubrium of the sternum. They are usually metastases, but the most common malignant-primary-tumor is chondrosarcoma. ⋯ The following authors have nothing to disclose: José González García, Sebastian Peñafiel, Eugenia Libreros Niño, Diana Baquero Velandia, Carlos Jordá Aragón, Ángel García ZarzaNo Product/Research Disclosure Information.